Compare Guardant Health Inc. Common Stock (GH) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs GSK plc — how do they compare? Guardant Health Inc. Common Stock trades at $168.44 (market cap $22.22B), while GSK plc trades at $46.82 (market cap $91.88B). The key difference: GSK plc is far larger — about 4.1× Guardant Health Inc. Common Stock's market cap, and GSK plc pays a 3.9% dividend while Guardant Health Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 0 Days and GSK plc for 93 Days on average.
| GH | GSK | |
|---|---|---|
Market Cap | $22.22B | $91.88B |
Volume | 1,589,453 | 7,730,529 |
Sector | Health | Health |
52-Week High | $187.22 | $61.18 |
52-Week Low | $61.73 | $43.24 |
Typical Hold Time | 0 Days | 93 Days |
Enterprise Value | $22.86B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
